Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hepatitis C | 20 | 2024 | 1597 | 4.270 |
Why?
|
Hepatitis C, Chronic | 10 | 2023 | 1032 | 2.860 |
Why?
|
Rwanda | 34 | 2022 | 672 | 2.460 |
Why?
|
Antiviral Agents | 17 | 2024 | 3050 | 2.320 |
Why?
|
Hepacivirus | 14 | 2024 | 1343 | 1.960 |
Why?
|
Hepatitis B virus | 4 | 2023 | 530 | 0.830 |
Why?
|
Developing Countries | 11 | 2024 | 2911 | 0.770 |
Why?
|
Child Mortality | 2 | 2019 | 204 | 0.670 |
Why?
|
Hepatitis, Viral, Human | 1 | 2020 | 141 | 0.660 |
Why?
|
Antiretroviral Therapy, Highly Active | 3 | 2018 | 1899 | 0.660 |
Why?
|
Africa South of the Sahara | 4 | 2023 | 751 | 0.600 |
Why?
|
Uridine Monophosphate | 1 | 2018 | 67 | 0.600 |
Why?
|
Poverty | 9 | 2023 | 2714 | 0.570 |
Why?
|
Fluorenes | 1 | 2018 | 160 | 0.570 |
Why?
|
Delivery of Health Care | 6 | 2022 | 5370 | 0.570 |
Why?
|
Pregnancy Complications, Infectious | 4 | 2024 | 2187 | 0.560 |
Why?
|
Rural Population | 9 | 2023 | 2317 | 0.550 |
Why?
|
Health Services Accessibility | 12 | 2024 | 5508 | 0.550 |
Why?
|
HIV Infections | 13 | 2023 | 17533 | 0.460 |
Why?
|
Infant Mortality | 1 | 2018 | 751 | 0.440 |
Why?
|
Patient Acceptance of Health Care | 4 | 2020 | 3230 | 0.430 |
Why?
|
Benzimidazoles | 1 | 2018 | 864 | 0.430 |
Why?
|
Anti-Retroviral Agents | 3 | 2018 | 1787 | 0.410 |
Why?
|
Hepatitis B | 3 | 2023 | 707 | 0.400 |
Why?
|
Wounds and Injuries | 3 | 2021 | 2511 | 0.400 |
Why?
|
Medicaid | 3 | 2024 | 2833 | 0.400 |
Why?
|
Liver Cirrhosis | 3 | 2023 | 1959 | 0.390 |
Why?
|
Carbamates | 2 | 2022 | 191 | 0.350 |
Why?
|
Viral Load | 7 | 2019 | 3386 | 0.350 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2023 | 2329 | 0.340 |
Why?
|
HIV | 2 | 2018 | 1585 | 0.340 |
Why?
|
Cause of Death | 3 | 2019 | 3708 | 0.330 |
Why?
|
Infectious Disease Transmission, Vertical | 3 | 2024 | 1354 | 0.300 |
Why?
|
Humans | 72 | 2024 | 765968 | 0.290 |
Why?
|
Hospitals, District | 5 | 2024 | 115 | 0.290 |
Why?
|
Anti-HIV Agents | 3 | 2018 | 4559 | 0.270 |
Why?
|
Liver Neoplasms | 1 | 2023 | 4353 | 0.270 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2015 | 2203 | 0.270 |
Why?
|
Autopsy | 3 | 2019 | 1011 | 0.270 |
Why?
|
Cost of Illness | 4 | 2022 | 1950 | 0.260 |
Why?
|
Primary Health Care | 4 | 2020 | 4736 | 0.260 |
Why?
|
Rural Health Services | 4 | 2021 | 393 | 0.250 |
Why?
|
Hepatitis B, Chronic | 2 | 2023 | 412 | 0.240 |
Why?
|
Public Health | 1 | 2017 | 2680 | 0.230 |
Why?
|
Depressive Disorder, Major | 1 | 2021 | 4808 | 0.220 |
Why?
|
Quality Assurance, Health Care | 1 | 2013 | 2172 | 0.210 |
Why?
|
Health Expenditures | 3 | 2021 | 2387 | 0.210 |
Why?
|
Adult | 28 | 2024 | 223044 | 0.210 |
Why?
|
Interviews as Topic | 3 | 2019 | 2739 | 0.210 |
Why?
|
Hospitals, Public | 2 | 2023 | 203 | 0.200 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3100 | 0.200 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3223 | 0.200 |
Why?
|
Genotype | 4 | 2022 | 13024 | 0.200 |
Why?
|
Aminoisobutyric Acids | 1 | 2022 | 39 | 0.200 |
Why?
|
Malawi | 2 | 2020 | 315 | 0.190 |
Why?
|
Ethiopia | 2 | 2022 | 485 | 0.190 |
Why?
|
Cross Infection | 2 | 2022 | 1427 | 0.190 |
Why?
|
Postnatal Care | 1 | 2024 | 275 | 0.190 |
Why?
|
Bangladesh | 2 | 2021 | 745 | 0.190 |
Why?
|
Kenya | 2 | 2021 | 758 | 0.180 |
Why?
|
Pandemics | 2 | 2021 | 8703 | 0.180 |
Why?
|
Female | 32 | 2024 | 396112 | 0.180 |
Why?
|
Health Promotion | 1 | 2013 | 2208 | 0.180 |
Why?
|
Pharmacy | 1 | 2022 | 92 | 0.180 |
Why?
|
Cross-Sectional Studies | 11 | 2024 | 26318 | 0.180 |
Why?
|
Ambulatory Care | 3 | 2024 | 2778 | 0.180 |
Why?
|
Nutrition Disorders | 1 | 2021 | 203 | 0.180 |
Why?
|
Leucine | 1 | 2022 | 546 | 0.170 |
Why?
|
Cyclopropanes | 1 | 2022 | 437 | 0.170 |
Why?
|
Proline | 1 | 2022 | 453 | 0.170 |
Why?
|
Lactams, Macrocyclic | 1 | 2022 | 318 | 0.170 |
Why?
|
Health Policy | 3 | 2024 | 2698 | 0.170 |
Why?
|
Prospective Studies | 7 | 2022 | 54802 | 0.170 |
Why?
|
Senegal | 1 | 2020 | 257 | 0.170 |
Why?
|
Death, Sudden | 1 | 2022 | 300 | 0.170 |
Why?
|
Quinoxalines | 1 | 2022 | 296 | 0.170 |
Why?
|
Delivery of Health Care, Integrated | 2 | 2021 | 953 | 0.170 |
Why?
|
Nepal | 1 | 2020 | 301 | 0.160 |
Why?
|
Colistin | 1 | 2019 | 46 | 0.160 |
Why?
|
Quality Improvement | 2 | 2015 | 3853 | 0.160 |
Why?
|
Crohn Disease | 2 | 2022 | 2283 | 0.160 |
Why?
|
Pneumonia, Ventilator-Associated | 1 | 2022 | 279 | 0.160 |
Why?
|
Hospitals, Rural | 2 | 2020 | 175 | 0.160 |
Why?
|
Drug Resistance, Multiple, Bacterial | 2 | 2021 | 592 | 0.150 |
Why?
|
Haiti | 1 | 2020 | 553 | 0.150 |
Why?
|
Prenatal Care | 2 | 2024 | 1160 | 0.150 |
Why?
|
Africa | 2 | 2023 | 725 | 0.150 |
Why?
|
Seroepidemiologic Studies | 4 | 2023 | 404 | 0.150 |
Why?
|
Klebsiella Infections | 1 | 2019 | 146 | 0.150 |
Why?
|
Infant, Newborn | 7 | 2022 | 26346 | 0.150 |
Why?
|
Outpatient Clinics, Hospital | 1 | 2020 | 394 | 0.140 |
Why?
|
Klebsiella pneumoniae | 1 | 2019 | 253 | 0.140 |
Why?
|
Postpartum Period | 1 | 2024 | 1205 | 0.140 |
Why?
|
Aspartate Aminotransferases | 1 | 2018 | 415 | 0.140 |
Why?
|
Adolescent | 14 | 2022 | 88835 | 0.140 |
Why?
|
Middle Aged | 18 | 2024 | 223009 | 0.140 |
Why?
|
Male | 23 | 2024 | 363698 | 0.140 |
Why?
|
Case Management | 1 | 2018 | 277 | 0.130 |
Why?
|
Surgical Equipment | 1 | 2016 | 58 | 0.130 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2020 | 12240 | 0.130 |
Why?
|
Safe Sex | 1 | 2017 | 144 | 0.130 |
Why?
|
Nutrition Surveys | 1 | 2023 | 1741 | 0.130 |
Why?
|
Urinary Tract Infections | 1 | 2022 | 805 | 0.130 |
Why?
|
Alanine Transaminase | 1 | 2018 | 607 | 0.130 |
Why?
|
Tanzania | 1 | 2020 | 1407 | 0.130 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2018 | 258 | 0.130 |
Why?
|
Referral and Consultation | 2 | 2020 | 3615 | 0.120 |
Why?
|
Treatment Failure | 1 | 2022 | 2652 | 0.120 |
Why?
|
Thymidine | 1 | 2015 | 294 | 0.120 |
Why?
|
Health Status Indicators | 1 | 2021 | 966 | 0.120 |
Why?
|
Prevalence | 6 | 2023 | 15842 | 0.120 |
Why?
|
Refugees | 1 | 2023 | 614 | 0.120 |
Why?
|
Pregnancy | 6 | 2024 | 30260 | 0.120 |
Why?
|
Treatment Outcome | 7 | 2021 | 65188 | 0.120 |
Why?
|
Community Health Services | 2 | 2018 | 657 | 0.120 |
Why?
|
Anti-Infective Agents | 1 | 2022 | 986 | 0.120 |
Why?
|
Clinical Laboratory Techniques | 1 | 2020 | 747 | 0.120 |
Why?
|
India | 4 | 2024 | 2334 | 0.120 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 1 | 2021 | 705 | 0.120 |
Why?
|
Endemic Diseases | 1 | 2015 | 189 | 0.110 |
Why?
|
World Health Organization | 2 | 2017 | 1328 | 0.110 |
Why?
|
Infant, Low Birth Weight | 1 | 2018 | 871 | 0.110 |
Why?
|
Syphilis | 1 | 2016 | 243 | 0.110 |
Why?
|
Infant, Newborn, Diseases | 1 | 2018 | 587 | 0.100 |
Why?
|
Young Adult | 13 | 2023 | 59889 | 0.100 |
Why?
|
Feasibility Studies | 1 | 2024 | 5302 | 0.100 |
Why?
|
Health Resources | 2 | 2017 | 949 | 0.100 |
Why?
|
Survival | 1 | 2013 | 160 | 0.100 |
Why?
|
Health Services | 1 | 2017 | 756 | 0.100 |
Why?
|
Staphylococcal Infections | 1 | 2021 | 1393 | 0.100 |
Why?
|
Hospitals | 2 | 2023 | 3888 | 0.100 |
Why?
|
Sulfonamides | 1 | 2022 | 1984 | 0.100 |
Why?
|
Infant | 7 | 2020 | 36386 | 0.100 |
Why?
|
Food Supply | 1 | 2018 | 544 | 0.100 |
Why?
|
Qualitative Research | 2 | 2020 | 3139 | 0.100 |
Why?
|
Multilocus Sequence Typing | 2 | 2021 | 102 | 0.090 |
Why?
|
HIV-1 | 2 | 2018 | 6944 | 0.090 |
Why?
|
Colitis, Ulcerative | 1 | 2022 | 1915 | 0.090 |
Why?
|
RNA, Viral | 1 | 2018 | 2864 | 0.090 |
Why?
|
Risk Factors | 8 | 2021 | 74840 | 0.080 |
Why?
|
CD4 Lymphocyte Count | 1 | 2016 | 2587 | 0.080 |
Why?
|
Socioeconomic Factors | 2 | 2021 | 7838 | 0.080 |
Why?
|
Child, Preschool | 5 | 2020 | 42500 | 0.080 |
Why?
|
Chronic Disease | 3 | 2023 | 9347 | 0.080 |
Why?
|
Social Support | 2 | 2018 | 2192 | 0.080 |
Why?
|
Retrospective Studies | 11 | 2023 | 81514 | 0.080 |
Why?
|
Health Services Needs and Demand | 2 | 2016 | 1406 | 0.080 |
Why?
|
Hepatitis C Antibodies | 2 | 2019 | 151 | 0.080 |
Why?
|
Infant, Premature | 1 | 2018 | 2122 | 0.080 |
Why?
|
United States | 4 | 2024 | 72903 | 0.080 |
Why?
|
Hypertension | 3 | 2024 | 8626 | 0.080 |
Why?
|
Sepsis | 1 | 2022 | 2606 | 0.080 |
Why?
|
Medical Oncology | 1 | 2020 | 2339 | 0.070 |
Why?
|
Insurance, Health | 2 | 2017 | 2521 | 0.070 |
Why?
|
Inflammatory Bowel Diseases | 1 | 2022 | 2429 | 0.070 |
Why?
|
Monitoring, Physiologic | 1 | 2015 | 1792 | 0.070 |
Why?
|
Parents | 2 | 2018 | 3592 | 0.070 |
Why?
|
Practice Guidelines as Topic | 1 | 2024 | 7425 | 0.070 |
Why?
|
Mass Screening | 2 | 2019 | 5446 | 0.070 |
Why?
|
Social Class | 1 | 2015 | 2007 | 0.060 |
Why?
|
Registries | 1 | 2022 | 8297 | 0.060 |
Why?
|
Politics | 2 | 2024 | 822 | 0.060 |
Why?
|
Aged | 7 | 2022 | 171117 | 0.060 |
Why?
|
Surgical Procedures, Operative | 1 | 2016 | 1941 | 0.060 |
Why?
|
Medication Adherence | 1 | 2016 | 2192 | 0.060 |
Why?
|
Communication | 1 | 2017 | 3916 | 0.050 |
Why?
|
Quality of Health Care | 2 | 2018 | 4300 | 0.050 |
Why?
|
Klebsiella | 1 | 2022 | 49 | 0.050 |
Why?
|
Blood Banks | 1 | 2023 | 108 | 0.050 |
Why?
|
Sierra Leone | 1 | 2023 | 171 | 0.050 |
Why?
|
Ghana | 1 | 2023 | 333 | 0.050 |
Why?
|
Patient Satisfaction | 1 | 2013 | 3475 | 0.050 |
Why?
|
Tunisia | 1 | 2020 | 39 | 0.050 |
Why?
|
Vital Signs | 1 | 2022 | 147 | 0.050 |
Why?
|
Diabetes Mellitus | 2 | 2020 | 5891 | 0.050 |
Why?
|
Guatemala | 1 | 2021 | 161 | 0.040 |
Why?
|
Case-Control Studies | 1 | 2018 | 22223 | 0.040 |
Why?
|
Egypt | 1 | 2020 | 100 | 0.040 |
Why?
|
Chile | 1 | 2021 | 258 | 0.040 |
Why?
|
Retreatment | 1 | 2022 | 598 | 0.040 |
Why?
|
Disk Diffusion Antimicrobial Tests | 1 | 2019 | 10 | 0.040 |
Why?
|
Logistic Models | 3 | 2019 | 13266 | 0.040 |
Why?
|
Policy Making | 1 | 2023 | 546 | 0.040 |
Why?
|
Bacterial Typing Techniques | 1 | 2019 | 263 | 0.040 |
Why?
|
Quality of Life | 1 | 2020 | 13462 | 0.040 |
Why?
|
Child | 4 | 2022 | 80564 | 0.040 |
Why?
|
Social Control Policies | 1 | 2017 | 9 | 0.040 |
Why?
|
Directly Observed Therapy | 1 | 2018 | 139 | 0.040 |
Why?
|
Electronic Health Records | 1 | 2015 | 4873 | 0.030 |
Why?
|
Multivariate Analysis | 2 | 2019 | 12056 | 0.030 |
Why?
|
Hepatitis B e Antigens | 1 | 2015 | 135 | 0.030 |
Why?
|
Remission Induction | 1 | 2020 | 2411 | 0.030 |
Why?
|
Respiratory Tract Diseases | 1 | 2020 | 744 | 0.030 |
Why?
|
Delayed Diagnosis | 1 | 2018 | 452 | 0.030 |
Why?
|
Hepatitis B Surface Antigens | 1 | 2015 | 294 | 0.030 |
Why?
|
Sentinel Surveillance | 1 | 2016 | 293 | 0.030 |
Why?
|
Population Density | 1 | 2014 | 193 | 0.030 |
Why?
|
Disease Management | 2 | 2015 | 2535 | 0.030 |
Why?
|
Professional-Family Relations | 1 | 2017 | 501 | 0.030 |
Why?
|
RNA | 1 | 2023 | 2717 | 0.030 |
Why?
|
Statistics, Nonparametric | 1 | 2018 | 2844 | 0.030 |
Why?
|
Community Health Centers | 1 | 2016 | 469 | 0.030 |
Why?
|
Medically Uninsured | 1 | 2017 | 838 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2022 | 6309 | 0.020 |
Why?
|
Social Stigma | 1 | 2018 | 788 | 0.020 |
Why?
|
Neoplasms | 1 | 2020 | 22340 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2018 | 21056 | 0.020 |
Why?
|
Sexually Transmitted Diseases | 1 | 2017 | 667 | 0.020 |
Why?
|
Vaccination | 1 | 2023 | 3426 | 0.020 |
Why?
|
Residence Characteristics | 1 | 2018 | 2116 | 0.020 |
Why?
|
Pregnancy Outcome | 1 | 2018 | 2966 | 0.020 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2021 | 3446 | 0.020 |
Why?
|
Heart Failure | 2 | 2021 | 11840 | 0.020 |
Why?
|
Models, Statistical | 1 | 2020 | 5089 | 0.020 |
Why?
|
Medicare | 1 | 2022 | 6823 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2020 | 15880 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2018 | 14751 | 0.010 |
Why?
|
Insulin | 1 | 2015 | 6599 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2015 | 10383 | 0.010 |
Why?
|
Hospitalization | 1 | 2016 | 10808 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2018 | 39193 | 0.010 |
Why?
|
Time Factors | 1 | 2017 | 40065 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2019 | 59489 | 0.010 |
Why?
|